Infliximab
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ankylosing Spondylitis
Conditions
Ankylosing Spondylitis
Trial Timeline
Oct 1, 2010 → Jun 1, 2012
NCT ID
NCT01220518About Infliximab
Infliximab is a phase 1 stage product being developed by Celltrion for Ankylosing Spondylitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01220518. Target conditions include Ankylosing Spondylitis.
What happened to similar drugs?
20 of 20 similar drugs in Ankylosing Spondylitis were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04922827 | Phase 2 | Completed |
| NCT01571219 | Phase 3 | Completed |
| NCT01571206 | Phase 1 | Completed |
| NCT01220518 | Phase 1 | Completed |
| NCT01217086 | Phase 3 | Completed |
Competing Products
20 competing products in Ankylosing Spondylitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Infliximab | Celltrion | Phase 1 | 29 |
| SUNPG1622 I dose + Placebo dose | Sun Pharmaceutical | Phase 2 | 27 |
| adalimumab | Eisai | Phase 3 | 40 |
| Ixekizumab + Placebo + Adalimumab | Eli Lilly | Phase 3 | 32 |
| Tramadol /acetaminophen + Diclofenac | Johnson & Johnson | Approved | 35 |
| Golimumab + Placebo | Johnson & Johnson | Phase 3 | 40 |
| Golimumab | Johnson & Johnson | Approved | 43 |
| SHR0302 + SHR0302 placebo | Jiangsu Hengrui Medicine | Phase 2/3 | 38 |
| placebo for risankizumab + risankizumab | AbbVie | Phase 2 | 35 |
| Adalimumab | AbbVie | Approved | 39 |
| Upadacitinib + Placebo | AbbVie | Phase 2 | 35 |
| Adalimumab | AbbVie | Pre-clinical | 26 |
| infliximab + Placebo | Merck | Phase 3 | 40 |
| Infliximab | Merck | Approved | 35 |
| Infliximab + Placebo + Naproxen | Merck | Phase 3 | 40 |
| Infliximab | Merck | Pre-clinical | 26 |
| Golimumab | Merck | Approved | 43 |
| Remicade | Merck | Approved | 43 |
| Remicade | Merck | Approved | 43 |
| Infliximab | Merck | Approved | 43 |